Three-year outcomes with first-line pembrolizumab, in patients with non-small-cell lung cancer and a PD-L1 tumor proportion score >90% Meeting Abstract
| Authors: | Ricciuti, B.; Arielle Elkrief, A.; Lin, J.; Altan, M.; Alessi, J.; Gandhi, M.; Pecci, F.; Lamberti, G.; Di Federico, A.; Wang, X.; Pabon, C.; Zhang, J.; Lindsey, J.; Sharma, B.; Felt, K.; Nishino, M.; Sholl, L.; Rodig, S.; Gainor, J.; Heymach, J.; Schoenfeld, A.; Awad, M. |
| Abstract Title: | Three-year outcomes with first-line pembrolizumab, in patients with non-small-cell lung cancer and a PD-L1 tumor proportion score >90% |
| Meeting Title: | 2023 World Conference on Lung Cancer (IASLC-WCLC) |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 18 |
| Issue: | 11 Suppl. |
| Meeting Dates: | 2023 Sep 9-11 |
| Meeting Location: | Singapore |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-11-01 |
| Start Page: | S77 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2023.09.077 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: OA14.04 -- Source: Cinahl |
